AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. MDGL
  4. [Form 4] Madrigal Pharmaceuticals, Inc. Insider Trading Activity

[Form 4] Madrigal Pharmaceuticals, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Kenneth Bate, Director at Madrigal Pharmaceuticals (MDGL), reported two significant equity transactions on June 20, 2025:

  • Received 715 restricted stock units (RSUs) at $0, bringing total direct common stock ownership to 2,627 shares
  • Granted stock options to purchase 1,290 shares at an exercise price of $285.73 per share

Both the RSUs and stock options are scheduled to vest at the company's 2026 annual stockholder meeting, contingent on Bate's continued service as director. The stock options have a ten-year term, expiring on June 20, 2035. The transactions were reported via Form 4 filing, with Mardi Dier signing as attorney-in-fact on June 24, 2025.

Kenneth Bate, Direttore presso Madrigal Pharmaceuticals (MDGL), ha comunicato due importanti operazioni azionarie il 20 giugno 2025:

  • Ha ricevuto 715 unit脿 azionarie vincolate (RSU) a $0, portando il totale delle azioni ordinarie possedute direttamente a 2.627
  • Gli sono state assegnate opzioni su azioni per acquistare 1.290 azioni a un prezzo di esercizio di $285,73 per azione

Sia le RSU che le opzioni su azioni matureranno durante l'assemblea annuale degli azionisti del 2026, a condizione che Bate continui a ricoprire il ruolo di direttore. Le opzioni hanno una durata di dieci anni, con scadenza il 20 giugno 2035. Le operazioni sono state segnalate tramite il modulo Form 4, firmato da Mardi Dier in qualit脿 di procuratore il 24 giugno 2025.

Kenneth Bate, Director en Madrigal Pharmaceuticals (MDGL), inform贸 dos importantes transacciones de acciones el 20 de junio de 2025:

  • 搁别肠颈产颈贸 715 unidades restringidas de acciones (RSU) a $0, elevando su propiedad directa total de acciones comunes a 2,627
  • Se le otorgaron opciones para comprar 1,290 acciones a un precio de ejercicio de $285.73 por acci贸n

Tanto las RSU como las opciones de acciones est谩n programadas para consolidarse en la reuni贸n anual de accionistas de la compa帽铆a en 2026, siempre que Bate contin煤e en su cargo como director. Las opciones tienen un plazo de diez a帽os, venciendo el 20 de junio de 2035. Las transacciones fueron reportadas mediante la presentaci贸n del Formulario 4, firmado por Mardi Dier como apoderado el 24 de junio de 2025.

旒�雱れ姢 氩犾澊韸�, 毵堧摐毽皥 韺岆鞀堩嫲旎姢 (MDGL) 鞚挫偓雼橁粯靹� 2025雲� 6鞗� 20鞚� 霊� 瓯挫潣 欤检殧 欤检嫕 瓯半灅毳� 氤搓碃頃橃榾鞀惦媹雼�:

  • 0雼煬鞐� 715臧滌潣 鞝滍暅 欤检嫕 雼渼(RSU)毳� 靾橂牴頃橃棳 歆侅爲 氤挫湢頃� 氤错喌欤� 齑濎垬臧� 2,627欤缄皜 霅橃棃鞀惦媹雼�
  • 欤茧嫻 285.73雼煬 頄夓偓臧赌瓴╈溂搿� 1,290欤�毳� 毵れ垬頃� 靾� 鞛堧姅 鞀ろ啞鞓奠厴鞚� 攵�鞐皼鞎橃姷雼堧嫟

RSU鞕� 鞀ろ啞鞓奠厴 氇憪 氩犾澊韸� 鞚挫偓臧� 瓿勳啀 鞚挫偓歆侅潉 鞙犾頃橂姅 臁瓣贝鞙茧, 2026雲� 鞐半 欤检＜齑濏殞鞐愳劀 氩犾姢韺呺悹 鞓堨爼鞛呺媹雼�. 鞀ろ啞鞓奠厴鞚� 鞙犿毃旮瓣皠鞚� 10雲勳溂搿�, 2035雲� 6鞗� 20鞚� 毵岆霅╇媹雼�. 頃措嫻 瓯半灅電� 2025雲� 6鞗� 24鞚� 氩曥爼雽�毽澑鞚� 毵堧敂 霐旍柎臧� 靹滊獏頃� Form 4 鞁犼碃靹滊 氤搓碃霅橃棃鞀惦媹雼�.

Kenneth Bate, Directeur chez Madrigal Pharmaceuticals (MDGL), a d茅clar茅 deux transactions importantes sur actions le 20 juin 2025 :

  • A re莽u 715 unit茅s d'actions restreintes (RSU) 脿 0 $, portant sa d茅tention directe totale d'actions ordinaires 脿 2 627
  • Sees ont accord茅 des options d'achat de 1 290 actions 脿 un prix d'exercice de 285,73 $ par action

Les RSU et les options d'achat d'actions doivent 锚tre acquises lors de l'assembl茅e annuelle des actionnaires de 2026, sous r茅serve que Bate continue 脿 servir en tant que directeur. Les options ont une dur茅e de dix ans et expirent le 20 juin 2035. Les transactions ont 茅t茅 d茅clar茅es via le d茅p么t du formulaire 4, sign茅 par Mardi Dier en tant que mandataire le 24 juin 2025.

Kenneth Bate, Direktor bei Madrigal Pharmaceuticals (MDGL), meldete am 20. Juni 2025 zwei bedeutende Aktiengesch盲fte:

  • Er erhielt 715 Restricted Stock Units (RSUs) zu einem Preis von 0 $, wodurch sein direkter Bestand an Stammaktien auf 2.627 Aktien anstieg
  • Er erhielt Aktienoptionen zum Kauf von 1.290 Aktien zu einem Aus眉bungspreis von 285,73 $ pro Aktie

Sowohl die RSUs als auch die Aktienoptionen sollen auf der Hauptversammlung 2026 des Unternehmens vesten, vorausgesetzt, Bate bleibt weiterhin als Direktor t盲tig. Die Aktienoptionen haben eine Laufzeit von zehn Jahren und laufen am 20. Juni 2035 ab. Die Transaktionen wurden 眉ber die Formular-4-Meldung gemeldet, die am 24. Juni 2025 von Mardi Dier als Bevollm盲chtigter unterzeichnet wurde.

Positive
  • None.
Negative
  • None.

Kenneth Bate, Direttore presso Madrigal Pharmaceuticals (MDGL), ha comunicato due importanti operazioni azionarie il 20 giugno 2025:

  • Ha ricevuto 715 unit脿 azionarie vincolate (RSU) a $0, portando il totale delle azioni ordinarie possedute direttamente a 2.627
  • Gli sono state assegnate opzioni su azioni per acquistare 1.290 azioni a un prezzo di esercizio di $285,73 per azione

Sia le RSU che le opzioni su azioni matureranno durante l'assemblea annuale degli azionisti del 2026, a condizione che Bate continui a ricoprire il ruolo di direttore. Le opzioni hanno una durata di dieci anni, con scadenza il 20 giugno 2035. Le operazioni sono state segnalate tramite il modulo Form 4, firmato da Mardi Dier in qualit脿 di procuratore il 24 giugno 2025.

Kenneth Bate, Director en Madrigal Pharmaceuticals (MDGL), inform贸 dos importantes transacciones de acciones el 20 de junio de 2025:

  • 搁别肠颈产颈贸 715 unidades restringidas de acciones (RSU) a $0, elevando su propiedad directa total de acciones comunes a 2,627
  • Se le otorgaron opciones para comprar 1,290 acciones a un precio de ejercicio de $285.73 por acci贸n

Tanto las RSU como las opciones de acciones est谩n programadas para consolidarse en la reuni贸n anual de accionistas de la compa帽铆a en 2026, siempre que Bate contin煤e en su cargo como director. Las opciones tienen un plazo de diez a帽os, venciendo el 20 de junio de 2035. Las transacciones fueron reportadas mediante la presentaci贸n del Formulario 4, firmado por Mardi Dier como apoderado el 24 de junio de 2025.

旒�雱れ姢 氩犾澊韸�, 毵堧摐毽皥 韺岆鞀堩嫲旎姢 (MDGL) 鞚挫偓雼橁粯靹� 2025雲� 6鞗� 20鞚� 霊� 瓯挫潣 欤检殧 欤检嫕 瓯半灅毳� 氤搓碃頃橃榾鞀惦媹雼�:

  • 0雼煬鞐� 715臧滌潣 鞝滍暅 欤检嫕 雼渼(RSU)毳� 靾橂牴頃橃棳 歆侅爲 氤挫湢頃� 氤错喌欤� 齑濎垬臧� 2,627欤缄皜 霅橃棃鞀惦媹雼�
  • 欤茧嫻 285.73雼煬 頄夓偓臧赌瓴╈溂搿� 1,290欤�毳� 毵れ垬頃� 靾� 鞛堧姅 鞀ろ啞鞓奠厴鞚� 攵�鞐皼鞎橃姷雼堧嫟

RSU鞕� 鞀ろ啞鞓奠厴 氇憪 氩犾澊韸� 鞚挫偓臧� 瓿勳啀 鞚挫偓歆侅潉 鞙犾頃橂姅 臁瓣贝鞙茧, 2026雲� 鞐半 欤检＜齑濏殞鞐愳劀 氩犾姢韺呺悹 鞓堨爼鞛呺媹雼�. 鞀ろ啞鞓奠厴鞚� 鞙犿毃旮瓣皠鞚� 10雲勳溂搿�, 2035雲� 6鞗� 20鞚� 毵岆霅╇媹雼�. 頃措嫻 瓯半灅電� 2025雲� 6鞗� 24鞚� 氩曥爼雽�毽澑鞚� 毵堧敂 霐旍柎臧� 靹滊獏頃� Form 4 鞁犼碃靹滊 氤搓碃霅橃棃鞀惦媹雼�.

Kenneth Bate, Directeur chez Madrigal Pharmaceuticals (MDGL), a d茅clar茅 deux transactions importantes sur actions le 20 juin 2025 :

  • A re莽u 715 unit茅s d'actions restreintes (RSU) 脿 0 $, portant sa d茅tention directe totale d'actions ordinaires 脿 2 627
  • Sees ont accord茅 des options d'achat de 1 290 actions 脿 un prix d'exercice de 285,73 $ par action

Les RSU et les options d'achat d'actions doivent 锚tre acquises lors de l'assembl茅e annuelle des actionnaires de 2026, sous r茅serve que Bate continue 脿 servir en tant que directeur. Les options ont une dur茅e de dix ans et expirent le 20 juin 2035. Les transactions ont 茅t茅 d茅clar茅es via le d茅p么t du formulaire 4, sign茅 par Mardi Dier en tant que mandataire le 24 juin 2025.

Kenneth Bate, Direktor bei Madrigal Pharmaceuticals (MDGL), meldete am 20. Juni 2025 zwei bedeutende Aktiengesch盲fte:

  • Er erhielt 715 Restricted Stock Units (RSUs) zu einem Preis von 0 $, wodurch sein direkter Bestand an Stammaktien auf 2.627 Aktien anstieg
  • Er erhielt Aktienoptionen zum Kauf von 1.290 Aktien zu einem Aus眉bungspreis von 285,73 $ pro Aktie

Sowohl die RSUs als auch die Aktienoptionen sollen auf der Hauptversammlung 2026 des Unternehmens vesten, vorausgesetzt, Bate bleibt weiterhin als Direktor t盲tig. Die Aktienoptionen haben eine Laufzeit von zehn Jahren und laufen am 20. Juni 2035 ab. Die Transaktionen wurden 眉ber die Formular-4-Meldung gemeldet, die am 24. Juni 2025 von Mardi Dier als Bevollm盲chtigter unterzeichnet wurde.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BATE KENNETH
(Last) (First) (Middle)
C/O MADRIGAL PHARMACEUTICALS, INC.
200 BARR HARBOR DRIVE, SUITE 400
(Street)
WEST CONSHOHOCKEN PA 19428
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MADRIGAL PHARMACEUTICALS, INC. [ MDGL ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/20/2025 A(1) 715 A $0 2,627 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $285.73 06/20/2025 A 1,290 (2) 06/20/2035 Common Stock 1,290 $0 1,290 D
Explanation of Responses:
1. Represents a grant of restricted stock units, which vest on the date of the Issuer's annual meeting of stockholders to be held in 2026, provided the Reporting Person continues in service with the Issuer on such date.
2. The option vests as to 100% of underlying shares on the date of the Issuer's annual meeting of stockholders to be held in 2026, provided that the Reporting Person continues to serve as a director of the Issuer until such date.
Remarks:
/s/ Mardi Dier, as Attorney-in-Fact 06/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

What insider trading activity occurred at MDGL on June 20, 2025?

Director Kenneth Bate received two equity grants on June 20, 2025: (1) 715 restricted stock units that vest at the 2026 annual stockholder meeting, and (2) stock options to purchase 1,290 shares at an exercise price of $285.73, which also vest at the 2026 annual stockholder meeting.

How many MDGL shares does Kenneth Bate own after the June 2025 transaction?

Following the reported transaction, Kenneth Bate directly owns 2,627 shares of MDGL common stock, plus stock options for 1,290 shares that will vest at the 2026 annual stockholder meeting.

What is the exercise price of MDGL stock options granted to Kenneth Bate in June 2025?

The stock options were granted with an exercise price of $285.73 per share and expire on June 20, 2035.

When do Kenneth Bate's new MDGL equity grants vest?

Both the restricted stock units and stock options granted to Kenneth Bate will vest on the date of Madrigal Pharmaceuticals' annual meeting of stockholders to be held in 2026, contingent on his continued service as a director until that date.
Stock MDGL logo
Madrigal Pharmac

NASDAQ:MDGL

MDGL Rankings

#1482 Ranked by Market Cap
N/A Ranked by Dividends

MDGL Latest News

Jul 30, 2025
Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited
Jul 25, 2025
Madrigal Pharmaceuticals to Release Second-Quarter 2025 Financial Results and聽Host Webcast on August 5, 2025
Jul 22, 2025
Madrigal Pharmaceuticals Secures $500 Million in Senior Secured Credit from Blue Owl Managed Funds to Further Extend Leadership Position in MASH
Jul 16, 2025
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Jul 16, 2025
Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra鈩� (Resmetirom)

MDGL Latest SEC Filings

Jul 30, 2025
[8-K] Madrigal Pharmaceuticals, Inc. Reports Material Event
Jul 22, 2025
[Form 4] Madrigal Pharmaceuticals, Inc. Insider Trading Activity
Jul 22, 2025
[Form 4] Madrigal Pharmaceuticals, Inc. Insider Trading Activity
Jul 22, 2025
[8-K] Madrigal Pharmaceuticals, Inc. Reports Material Event
Jul 18, 2025
[144] Madrigal Pharmaceuticals, Inc. SEC Filing

MDGL Stock Data

6.44B
20.43M
8.74%
105.1%
17%
Biotechnology
Pharmaceutical Preparations
United States
WEST CONSHOHOCKEN